OrbiMed Raises $3.5 Billion Across Private Investment Funds
OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III.
- OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III.
- Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds.
- These new funds bring OrbiMeds assets under management to approximately $18 billion across public equity, private equity and credit/royalty strategies.
- OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds.